SCHEMBL5882017

SCHEMBL5882017

Cc1cc2ccc(C(=O)NS(=O)(=O)c3ccccc3)cc2n1Cc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 1/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
PPARG P37231 4/20 0.46
EGFR P00533 1/20 0.45
FLT1 P17948 3/20 0.45
FLT4 P35916 3/20 0.45
KDR P35968 3/20 0.45
PTPN1 P18031 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
GAA P10253 1/20 0.42
GNRHR P30968 1/20 0.42
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160116 0.85 PPARG (0.59) CCR2HDAC8HDAC1HDAC2HDAC6
SCHEMBL5882169 0.84 CCR2 (0.50) CCR2HDAC8HDAC1HDAC2HDAC6
SCHEMBL1160051 0.83 PPARG (0.67) HDAC8HDAC1HDAC2HDAC6HDAC9
SCHEMBL7654411 0.82 BCL2L1 (0.44) CCR2HDAC8HDAC1HDAC2HDAC6
SCHEMBL5882209 0.82 L3MBTL1 (0.49) CCR2HDAC8HDAC1HDAC2HDAC6
SCHEMBL5882680 0.81 MAPT (0.53) CCR2HDAC8HDAC1HDAC2HDAC6
SCHEMBL1160331 0.79 PPARG (0.57) HDAC8HDAC1HDAC2HDAC6HDAC9
SCHEMBL1160028 0.79 PPARG (0.62) HDAC8HDAC1HDAC2HDAC6HDAC9
SCHEMBL1160351 0.79 TP53 (0.51) CCR2PPARGTDP1TP53
SCHEMBL6171894 0.79 PPARG (0.61) HDAC8HDAC1HDAC2HDAC6HDAC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed
EP-1132087-A1 REMEDIES FOR POLYCYSTIC OVARY SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT CCR2 3441/4885HDAC8 1437/4885HDAC1 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.